Alok Khorana
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Venous Thromboembolism | 19 | 2007 | 15 |
Why?
| Neoplasms | 29 | 2003 | 239 |
Why?
| Thrombosis | 7 | 2003 | 105 |
Why?
| Anticoagulants | 12 | 2004 | 88 |
Why?
| Thromboembolism | 5 | 2004 | 27 |
Why?
| Medical Oncology | 6 | 2007 | 28 |
Why?
| Pancreatic Neoplasms | 5 | 2004 | 46 |
Why?
| Thromboplastin | 5 | 2007 | 21 |
Why?
| Antineoplastic Agents | 7 | 2001 | 190 |
Why?
| Venous Thrombosis | 5 | 2006 | 45 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2003 | 94 |
Why?
| Risk Assessment | 9 | 2007 | 324 |
Why?
| Humans | 53 | 2001 | 1856 |
Why?
| Primary Prevention | 2 | 2009 | 44 |
Why?
| Practice Guidelines as Topic | 4 | 2007 | 174 |
Why?
| Physician-Patient Relations | 3 | 2003 | 111 |
Why?
| Risk Factors | 14 | 2005 | 555 |
Why?
| Biological Markers | 5 | 2009 | 262 |
Why?
| Inpatients | 2 | 2006 | 46 |
Why?
| Aged | 19 | 2001 | 988 |
Why?
| Narration | 2 | 2010 | 18 |
Why?
| Prognosis | 9 | 2001 | 388 |
Why?
| Heparin, Low-Molecular-Weight | 5 | 2003 | 11 |
Why?
| Male | 25 | 2003 | 1553 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2005 | 121 |
Why?
| Awareness | 2 | 2009 | 25 |
Why?
| Fibrinolytic Agents | 2 | 2009 | 42 |
Why?
| Survival Analysis | 8 | 2004 | 205 |
Why?
| Blood Coagulation | 2 | 2009 | 57 |
Why?
| Neovascularization, Pathologic | 3 | 2004 | 64 |
Why?
| Humanities | 1 | 2010 | 6 |
Why?
| Middle Aged | 18 | 2001 | 1161 |
Why?
| Electronic Health Records | 1 | 2010 | 4 |
Why?
| Efficiency | 1 | 2010 | 17 |
Why?
| Humanism | 1 | 2010 | 6 |
Why?
| Gastrointestinal Neoplasms | 1 | 2010 | 20 |
Why?
| Carcinoma, Hepatocellular | 2 | 2007 | 53 |
Why?
| Hospital Mortality | 2 | 2006 | 60 |
Why?
| Female | 21 | 2003 | 1643 |
Why?
| Pulmonary Embolism | 2 | 2006 | 48 |
Why?
| Teaching | 1 | 2010 | 89 |
Why?
| Liver Neoplasms | 2 | 2007 | 97 |
Why?
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 7 |
Why?
| Software | 1 | 2010 | 92 |
Why?
| Ambulatory Care | 2 | 2007 | 106 |
Why?
| Education, Medical, Graduate | 1 | 2010 | 70 |
Why?
| Tissue Array Analysis | 1 | 2009 | 27 |
Why?
| Colorectal Neoplasms | 3 | 2004 | 55 |
Why?
| Publishing | 1 | 2009 | 30 |
Why?
| Referral and Consultation | 1 | 2010 | 134 |
Why?
| Lymphoma, Non-Hodgkin | 2 | 2001 | 41 |
Why?
| Anemia | 1 | 2008 | 60 |
Why?
| Internship and Residency | 2 | 2008 | 175 |
Why?
| Hospitalization | 2 | 2007 | 169 |
Why?
| Portal Vein | 1 | 2007 | 30 |
Why?
| Carcinoma | 1 | 2009 | 109 |
Why?
| Blood Transfusion | 1 | 2008 | 59 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 145 |
Why?
| Heparin | 2 | 2003 | 87 |
Why?
| Retrospective Studies | 8 | 2003 | 653 |
Why?
| Predictive Value of Tests | 4 | 2008 | 321 |
Why?
| Smad4 Protein | 1 | 2005 | 18 |
Why?
| Arterial Occlusive Diseases | 1 | 2006 | 36 |
Why?
| Neutropenia | 1 | 2006 | 42 |
Why?
| Models, Statistical | 1 | 2007 | 114 |
Why?
| Eponyms | 1 | 2003 | 2 |
Why?
| Continental Population Groups | 1 | 2005 | 85 |
Why?
| United States | 6 | 2003 | 604 |
Why?
| Euthanasia, Passive | 1 | 2003 | 11 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2004 | 20 |
Why?
| Antigens, CD | 2 | 2001 | 128 |
Why?
| Terminally Ill | 1 | 2003 | 7 |
Why?
| Aged, 80 and over | 7 | 2005 | 599 |
Why?
| Attitude to Death | 1 | 2003 | 29 |
Why?
| Treatment Outcome | 7 | 2001 | 661 |
Why?
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 17 |
Why?
| Prostatic Neoplasms | 1 | 2009 | 120 |
Why?
| T-Lymphocytes | 2 | 2001 | 182 |
Why?
| Dendritic Cells | 1 | 2004 | 60 |
Why?
| Tumor Markers, Biological | 1 | 2005 | 112 |
Why?
| Adenoviridae | 1 | 2003 | 60 |
Why?
| Colonic Neoplasms | 1 | 2003 | 63 |
Why?
| Models, Biological | 1 | 2008 | 410 |
Why?
| Receptor, Epidermal Growth Factor | 1 | 2003 | 54 |
Why?
| Dose-Response Relationship, Drug | 4 | 2001 | 431 |
Why?
| Antibodies, Monoclonal | 2 | 2001 | 241 |
Why?
| Macrophages | 1 | 2004 | 148 |
Why?
| Deltaretrovirus Infections | 1 | 2001 | 2 |
Why?
| Melanoma | 1 | 2003 | 87 |
Why?
| Antibodies, Neoplasm | 1 | 2001 | 28 |
Why?
| Multivariate Analysis | 4 | 2003 | 225 |
Why?
| Interferon-gamma | 1 | 2003 | 133 |
Why?
| Incidence | 3 | 2005 | 336 |
Why?
| Gene Therapy | 1 | 2003 | 89 |
Why?
| Deoxycytidine | 2 | 2010 | 20 |
Why?
| Antigens, Neoplasm | 1 | 2001 | 56 |
Why?
| Cohort Studies | 3 | 2005 | 332 |
Why?
| Prospective Studies | 5 | 2004 | 545 |
Why?
| P-Selectin | 2 | 2009 | 20 |
Why?
| Physician's Role | 2 | 2010 | 92 |
Why?
| Endothelium, Vascular | 1 | 2003 | 139 |
Why?
| Neoplasm Staging | 3 | 2007 | 125 |
Why?
| Warfarin | 3 | 2004 | 27 |
Why?
| Angiogenesis Inhibitors | 2 | 2005 | 15 |
Why?
| Adult | 8 | 2001 | 1317 |
Why?
| Prevalence | 2 | 2009 | 281 |
Why?
| Forecasting | 2 | 2005 | 147 |
Why?
| Adenocarcinoma | 2 | 2010 | 167 |
Why?
| Questionnaires | 2 | 2010 | 360 |
Why?
| New York | 2 | 2008 | 422 |
Why?
| Angiogenesis Inducing Agents | 2 | 2003 | 14 |
Why?
| Logistic Models | 2 | 2006 | 251 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2003 | 49 |
Why?
| HIV Infections | 1 | 2001 | 136 |
Why?
| Severity of Illness Index | 2 | 2005 | 358 |
Why?
| Immunohistochemistry | 2 | 2004 | 355 |
Why?
| Lymphoma, B-Cell | 2 | 2001 | 33 |
Why?
| Young Adult | 3 | 2008 | 380 |
Why?
| Literature | 1 | 2010 | 6 |
Why?
| Writing | 1 | 2010 | 14 |
Why?
| Feedback | 1 | 2010 | 54 |
Why?
| Leukocytosis | 1 | 2010 | 17 |
Why?
| Efficiency, Organizational | 1 | 2010 | 24 |
Why?
| Patient Selection | 2 | 2009 | 155 |
Why?
| Taxoids | 1 | 2010 | 12 |
Why?
| Fellowships and Scholarships | 1 | 2010 | 34 |
Why?
| Thrombophilia | 1 | 2010 | 10 |
Why?
| Stomach Neoplasms | 1 | 2010 | 28 |
Why?
| Injections | 1 | 2010 | 53 |
Why?
| Medication Adherence | 1 | 2010 | 19 |
Why?
| Fluorouracil | 1 | 2010 | 49 |
Why?
| Program Evaluation | 1 | 2010 | 115 |
Why?
| Fibrin Fibrinogen Degradation Products | 1 | 2009 | 16 |
Why?
| Cardiology | 1 | 2010 | 25 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2007 | 176 |
Why?
| Disease-Free Survival | 3 | 2001 | 102 |
Why?
| International Cooperation | 1 | 2009 | 42 |
Why?
| Pilot Projects | 1 | 2010 | 264 |
Why?
| Platelet Count | 1 | 2009 | 39 |
Why?
| Factor V | 1 | 2009 | 12 |
Why?
| Administration, Oral | 1 | 2010 | 170 |
Why?
| Infection | 1 | 2009 | 57 |
Why?
| Follow-Up Studies | 2 | 2001 | 553 |
Why?
| India | 1 | 2008 | 10 |
Why?
| Emigrants and Immigrants | 1 | 2008 | 9 |
Why?
| Health Care Surveys | 1 | 2010 | 91 |
Why?
| Curriculum | 1 | 2010 | 127 |
Why?
| Leukocyte Count | 1 | 2009 | 94 |
Why?
| C-Reactive Protein | 1 | 2009 | 54 |
Why?
| Comorbidity | 1 | 2010 | 190 |
Why?
| Physicians | 1 | 2010 | 104 |
Why?
| Drug Administration Schedule | 1 | 2009 | 191 |
Why?
| Patient Education as Topic | 1 | 2010 | 128 |
Why?
| Esophageal Neoplasms | 1 | 2010 | 37 |
Why?
| Prostatectomy | 1 | 2009 | 29 |
Why?
| Evidence-Based Medicine | 1 | 2009 | 125 |
Why?
| Internal Medicine | 1 | 2008 | 58 |
Why?
| Hepacivirus | 1 | 2007 | 15 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2008 | 39 |
Why?
| Kaplan-Meier Estimate | 1 | 2007 | 89 |
Why?
| Communication | 1 | 2010 | 116 |
Why?
| Capillaries | 1 | 2007 | 47 |
Why?
| Vascular Diseases | 1 | 2007 | 60 |
Why?
| Recurrence | 1 | 2009 | 261 |
Why?
| Population Surveillance | 1 | 2007 | 70 |
Why?
| Mortality | 1 | 2007 | 50 |
Why?
| Thymidine Phosphorylase | 1 | 2005 | 3 |
Why?
| Antigens, CD31 | 1 | 2005 | 17 |
Why?
| Radiotherapy, Adjuvant | 1 | 2005 | 49 |
Why?
| Microcirculation | 1 | 2005 | 49 |
Why?
| Sex Distribution | 1 | 2005 | 101 |
Why?
| Chemotherapy, Adjuvant | 1 | 2005 | 55 |
Why?
| Age Distribution | 1 | 2005 | 127 |
Why?
| Obesity | 1 | 2009 | 149 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 38 |
Why?
| Odds Ratio | 1 | 2006 | 157 |
Why?
| Chi-Square Distribution | 1 | 2005 | 179 |
Why?
| Probability | 1 | 2005 | 190 |
Why?
| Neoplasm Recurrence, Local | 1 | 2007 | 118 |
Why?
| Fibrinogen | 1 | 2005 | 45 |
Why?
| Liver Transplantation | 1 | 2007 | 54 |
Why?
| Microsatellite Repeats | 1 | 2004 | 24 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 68 |
Why?
| Eosinophils | 1 | 2004 | 30 |
Why?
| Leukemia | 1 | 2006 | 70 |
Why?
| Mast Cells | 1 | 2004 | 31 |
Why?
| Lymphoma | 1 | 2006 | 96 |
Why?
| Terminal Care | 1 | 2005 | 27 |
Why?
| France | 1 | 2003 | 13 |
Why?
| Anecdotes as Topic | 1 | 2003 | 9 |
Why?
| Thymidine | 1 | 2003 | 47 |
Why?
| History, 19th Century | 1 | 2003 | 40 |
Why?
| Injections, Intralesional | 1 | 2003 | 15 |
Why?
| beta 2-Microglobulin | 1 | 2003 | 17 |
Why?
| Umbilical Veins | 1 | 2003 | 46 |
Why?
| Survival Rate | 1 | 2005 | 250 |
Why?
| Killer Cells, Natural | 1 | 2004 | 62 |
Why?
| Analysis of Variance | 1 | 2005 | 339 |
Why?
| Family | 1 | 2005 | 101 |
Why?
| Sex Factors | 1 | 2005 | 284 |
Why?
| Terminology as Topic | 1 | 2003 | 81 |
Why?
| Research | 1 | 2003 | 124 |
Why?
| Age Factors | 1 | 2005 | 480 |
Why?
| Human T-lymphotropic virus 2 | 1 | 2001 | 1 |
Why?
| Neoplasm, Residual | 1 | 2001 | 19 |
Why?
| Human T-lymphotropic virus 1 | 1 | 2001 | 8 |
Why?
| Epstein-Barr Virus Infections | 1 | 2001 | 13 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2001 | 31 |
Why?
| Immunization, Passive | 1 | 2001 | 39 |
Why?
| Genetic Vectors | 1 | 2003 | 139 |
Why?
| Immunophenotyping | 1 | 2001 | 66 |
Why?
| Cell Division | 1 | 2003 | 273 |
Why?
| Tumor Virus Infections | 1 | 2001 | 31 |
Why?
| Interleukin-6 | 1 | 2003 | 145 |
Why?
| Bacterial Infections | 1 | 2001 | 88 |
Why?
| Time Factors | 1 | 2007 | 896 |
Why?
| Bone Marrow Cells | 1 | 2001 | 92 |
Why?
| Glycoproteins | 1 | 2001 | 113 |
Why?
| Cytokines | 1 | 2001 | 207 |
Why?
| Cells, Cultured | 1 | 2003 | 447 |
Why?
| Outpatients | 1 | 2010 | 29 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2010 | 29 |
Why?
| Drug Costs | 1 | 2008 | 22 |
Why?
| Thrombolytic Therapy | 1 | 2009 | 42 |
Why?
| Animals | 2 | 2001 | 1031 |
Why?
| Cost-Benefit Analysis | 1 | 2008 | 118 |
Why?
| Hepatitis C, Chronic | 1 | 2007 | 10 |
Why?
| Liver Cirrhosis | 1 | 2007 | 48 |
Why?
| Chorioallantoic Membrane | 1 | 2005 | 4 |
Why?
| Hemorrhage | 1 | 2007 | 103 |
Why?
| Chick Embryo | 1 | 2005 | 62 |
Why?
| Risk | 1 | 2006 | 203 |
Why?
| Placenta | 1 | 2005 | 48 |
Why?
| Binding Sites | 1 | 2005 | 213 |
Why?
| Endothelial Cells | 1 | 2005 | 80 |
Why?
| Protein Binding | 1 | 2005 | 256 |
Why?
| Cell Proliferation | 1 | 2005 | 227 |
Why?
| Mutation | 1 | 2005 | 340 |
Why?
| Mice | 1 | 2005 | 623 |
Why?
|
|
Khorana's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
